Cargando…

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

A subset of patients with familial platelet disorder with propensity to myeloid malignancy and germline RUNX1 mutation develops hematological malignancies, often myelodysplastic syndrome/acute myeloid leukemia, currently recognized in the 2016 WHO classification. Patients who develop hematologic mal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanagal-Shamanna, Rashmi, Loghavi, Sanam, DiNardo, Courtney D., Medeiros, L. Jeffrey, Garcia-Manero, Guillermo, Jabbour, Elias, Routbort, Mark J., Luthra, Rajyalakshmi, Bueso-Ramos, Carlos E., Khoury, Joseph D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622850/ https://www.ncbi.nlm.nih.gov/pubmed/28659335 http://dx.doi.org/10.3324/haematol.2017.167726

Ejemplares similares

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
por: Bannon, Sarah A., et al.
Publicado: (2021)

Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance
por: Lachowiez, Curtis A., et al.
Publicado: (2023)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience
por: El Hussein, Siba, et al.
Publicado: (2020)

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
por: Huang, Lanshan, et al.
Publicado: (2016)

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Myelodysplastic/ Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-institutional Collaborative Study from the Bone Marrow Pathology Group
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2022)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFβ-MYH11
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2012)

PB2481: OUTCOMES OF INDIVIDUALS WITH CLONAL HEMATOPOIESIS EVALUATED AT A CANCER CENTER
por: Chien, Kelly, et al.
Publicado: (2023)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing
por: Aitken, Marisa J L, et al.
Publicado: (2022)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
por: Boddu, Prajwal, et al.
Publicado: (2017)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_stlt4bjppbjrfs60nhd3hlsfpv